Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Manufacturing
Description
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-11 02:00 |
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
|
English | 13.6 KB | ||
| 2023-05-10 02:00 |
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim …
|
English | 9.0 KB | ||
| 2023-05-05 02:00 |
Addex Convenes Annual General Meeting 2023
|
English | 8.4 KB | ||
| 2023-05-04 02:00 |
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Cal…
|
English | 6.3 KB | ||
| 2023-04-05 02:00 |
Addex Completes $5.0 Million Equity Financing
|
English | 8.8 KB | ||
| 2023-04-04 02:00 |
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Mot…
|
English | 7.4 KB | ||
| 2023-04-03 02:00 |
Addex Raises $5.0 Million in Equity Financing
|
English | 8.6 KB | ||
| 2019-10-08 08:00 |
Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Progr…
|
English | 13.9 KB | ||
| 2019-09-30 08:00 |
Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update
|
English | 21.3 KB | ||
| 2019-09-25 08:00 |
ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERE…
|
English | 11.7 KB | ||
| 2019-09-24 08:00 |
Addex Therapeutics Submits Registration Statement with the U.S. SEC to Facilita…
|
English | 12.3 KB | ||
| 2019-08-27 08:00 |
Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target…
|
English | 12.2 KB |
Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Addex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Addex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
